Long-term safety and efficacy of imatinib in pulmonary arterial hypertension

Journal of Heart and Lung Transplantation

Volumn 34, Issue 11, 2015, Pages 1366-1375

  Frost, Adaani E ^a   Barst, Robyn J ^b   Hoeper, Marius M ^c   Chang, Hyuk Jae ^d   Frantz, Robert P ^e   Fukumoto, Yoshihiro ^f   Galié, Nazzareno ^g   Hassoun, Paul M ^h   Klose, Hans ⁱ   Matsubara, Hiromi ^j   Morrell, Nicholas W ^k   Peacock, Andrew J ^l   Pfeifer, Michael ^m   Simonneau, Gérald ⁿ   Tapson, Victor F ^o   Torres, Fernando ^p   Dario Vizza, Carmine ^q   Lawrence, David ^r   Yang, Wei ^r   Felser, James M ^r   Quinn, Deborah A ^r   Ghofrani, Hossein Ardeschir ^s   more..

^a HOUSTON METHODIST HOSPITAL   (United States)

^b New York Presbyterian Columbia University Medical Center   (United States)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d Yonsei University College of Medicine   (South Korea)

^e Mayo Clinic College of Medicine   (United States)

^f TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

ⁱ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^j NATIONAL HOSPITAL ORGANIZATION   (Japan)

^k UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^l GOLDEN JUBILEE NATIONAL HOSPITAL   (United Kingdom)

^m UNIVERSITY OF REGENSBURG   (Germany)

ⁿ BICÊTRE HOSPITAL   (France)

^o DUKE UNIVERSITY MEDICAL CENTER   (United States)

^p UNIVERSITY OF TEXAS AT DALLAS   (United States)

^q SAPIENZA UNIVERSITY OF ROME   (Italy)

^r NOVARTIS PHARMA AG   (Switzerland)

^s UNIVERSITY HOSPITAL GIESSEN   (Germany)

more..

Author keywords

efficacy; imatinib; long term; pulmonary arterial hypertension; safety

Indexed keywords

IMATINIB; PLACEBO; PROTEIN KINASE INHIBITOR;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BLOOD CLOTTING DISORDER; BRONCHITIS; CONTROLLED STUDY; COUGHING; DEATH; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FAINTNESS; FATIGUE; FEMALE; FEVER; HEADACHE; HEART RIGHT VENTRICLE FAILURE; HUMAN; HYPOKALEMIA; HYPOTENSION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUSCLE SPASM; NAUSEA; OROPHARYNX PAIN; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RASH; RECIPIENT; RESPIRATORY FAILURE; RHINOPHARYNGITIS; SUBDURAL HEMATOMA; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; ADOLESCENT; CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; EXERCISE TOLERANCE; FOLLOW UP; HEMODYNAMICS; HYPERTENSION, PULMONARY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PHYSIOLOGY; RETROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EXERCISE TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; IMATINIB MESYLATE; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84946473665     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2015.05.025     Document Type: Article

References (35)

1. V.V. McLaughlin Looking to the future: a new decade of pulmonary arterial hypertension therapy Eur Respir Rev 20 2011 262 269
2. R.J. Barst, L.J. Rubin, W.A. Long, and et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension N Engl J Med 334 1996 296 301
3. N. Galiè, H.A. Ghofrani, A. Torbicki, and et al. Sildenafil citrate therapy for pulmonary arterial hypertension N Engl J Med 353 2005 2148 2157
4. N. Galiè, H. Olschewski, R.J. Oudiz, and et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2 Circulation 117 2008 3010 3019
5. N. Galiè, B.H. Brundage, H.A. Ghofrani, and et al. Tadalafil therapy for pulmonary arterial hypertension Circulation 119 2009 2894 2903
6. L.J. Rubin, D.B. Badesch, R.J. Barst, and et al. Bosentan therapy for pulmonary arterial hypertension N Engl J Med 346 2002 896 903
7. H.-A. Ghofrani, N. Galiè, F. Grimminger, and et al. Riociguat for the treatment of pulmonary arterial hypertension N Engl J Med 369 2013 330 340
8. T. Pulido, Adzerikho Gi, R.N. Channick, and et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension N Engl J Med 369 2013 809 818
9. R.J. Barst, M. McGoon, V. McLaughlin, and et al. Beraprost therapy for pulmonary arterial hypertension J Am Coll Cardiol 41 2003 2119 2125
10. Z.C. Jing, K. Parikh, T. Pulido, and et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial Circulation 127 2013 624 633
11. K.M. Chin, D.B. Badesch, I.M. Robbins, and et al. Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study Am Heart J 167 2014 218 225
12. V.F. Tapson, M. Gomberg-Maitland, V.V. McLaughlin, and et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial Chest 129 2006 683 688
13. G. Simonneau, R.J. Barst, N. Galiè, and et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial Am J Respir Crit Care Med 165 2002 800 804
14. H. Olschewski, G. Simonneau, N. Galiè, and et al. Inhaled iloprost for severe pulmonary hypertension N Engl J Med 347 2002 322 329
15. V.V. McLaughlin, R.L. Benza, L.J. Rubin, and et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial J Am Coll Cardiol 55 2010 1915 1922
16. M. Humbert, O. Sitbon, A. Chaouat, and et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era Circulation 122 2010 156 163
17. R.L. Benza, D.P. Miller, R.J. Barst, D.B. Badesch, A.E. Frost, and M.D. McGoon An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry Chest 142 2012 448 456
18. S. Rich, B.H. Brundage, and P.S. Levy The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension Circulation 71 1985 1191 1196
19. M. Humbert, G. Monti, M. Fartoukh, and et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients Eur Respir J 11 1998 554 559
20. D. Montani, F. Perros, N. Gambaryan, and et al. C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension Am J Respir Crit Care Med 184 2011 116 123
21. F. Perros, D. Montani, P. Dorfmuller, and et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension Am J Respir Crit Care Med 178 2008 81 88
22. N. Gambaryan, F. Perros, D. Montani, and et al. Targeting of c-kit+ haematopoietic progenitor cells prevents hypoxic pulmonary hypertension Eur Respir J 37 2011 1392 1399
23. R.T. Schermuly, E. Dony, H.A. Ghofrani, and et al. Reversal of experimental pulmonary hypertension by PDGF inhibition J Clin Invest 115 2005 2811 2821
24. H.A. Ghofrani, W. Seeger, and F. Grimminger Imatinib for the treatment of pulmonary arterial hypertension N Engl J Med 353 2005 1412 1413
25. K.C. Patterson, A. Weissmann, T. Ahmadi, and H.W. Farber Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension Ann Intern Med 145 2006 152 153
26. R. Souza, O. Sitbon, F. Parent, G. Simonneau, and M. Humbert Long term imatinib treatment in pulmonary arterial hypertension Thorax 61 2006 736
27. H.A. Ghofrani, N.W. Morrell, M.M. Hoeper, and et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy Am J Respir Crit Care Med 182 2010 1171 1177
28. M.M. Hoeper, R.J. Barst, R.C. Bourge, and et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study Circulation 127 2013 1128 1138
29. G. Simonneau, I.M. Robbin, M. Beghetti, and et al. Updated clinical classification of pulmonary hypertension J Am Coll Cardiol 54 1 Suppl 2009 S43 S54
30. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories ATS statement: guidelines for the six-minute walk test Am J Respir Crit Care Med 166 2002 111 117
31. G.E. D'Alonzo, R.J. Barst, S.M. Ayres, and et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry Ann Intern Med 115 1991 343 349
32. H. Mucke The role of imatinib in the treatment of pulmonary hypertension Drugs Today (Barc) 49 2013 203 211
33. M. Humbert Impression, sunset Circulation 127 2013 1098 1100
34. S.C. Mathai, M.A. Puhan, D. Lam, and R.A. Wise The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension Am J Respir Crit Care Med 186 2012 428 433
35. K.W. Song, J. Rifkind, B. Al-Beirouti, and et al. Subdural hematomas during CML therapy with imatinib mesylate Leuk Lymphoma 45 2004 1633 1636